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Text: Background:  Patients  undergoing  allogeneic  hematopoietic  stem  cell  transplant  (HSCT)  are  exposed  to  a  number  of
neurological  complications  that  may  be  related  to  drugs,  infections,  metabolic  alterations,  cerebrovascular  events  and
immune-­mediated  disorders  including  myositis,  myasthenia  gravis,  Guillain-­Barrè-­like  demyelinating  polyneuropathy  and
central  nervous  system  (CNS)  manifestations  of  graft  versus  host  disease  (GVHD).  The  multifactorial  etiology  of
neurological  complications  in  HSCT  patients  makes  diagnosis  difficult.  However  a  timely  and  rigorous  characterization  of
such  complications  should  be  obtained  in  the  attempt  to  avoid  fatal  outcomes  or  long-­term  effects.  Data  regarding
neurological  complications  in  HSCT  patients  derives  from  small  series  and  varies  largely  in  respect  to  incidence  and
severity.  Aim  of  this  study  is  to  describe  incidence,  characteristics  and  outcome  of  neurological  complications  in  a  large
series  of  consecutive  HSCT  patients.
Methods:  Data  were  retrieved  from  medical  records  of  777  patients  transplanted  from  January  2007  to  January  2017  in  3
Italian  centres.  Complications  affecting  either  central  or  peripheral  nervous  system  were  classified  based  on  their  etiology
(Maffini  et  al.  Biol  Blood  Marrow  Transplant.  2017;;23:388-­397)  and  time  of  onset  (from  days  0  to  30,  30  to  120,  120  to
180,  180  to  365,  and  post  day  365).
Results:  Overall  34  [median  age:  51.5  (19-­66)  years;;  F/M:  11/23;;  Caucasian  31]  of  the  777  patients  analysed  (4.4%)
presented  neurological  complications.  Among  these  patients,  19  (55.8%)  received  a  reduced-­intensity  HSCT,  15  (44.2%)
a  myeloablative  HSCT.  Donors  were  matched  related  in  10  (29.4%)  cases,  haploidentical  in  2  (5.9%),  and  matched  or
mismatched  unrelated  in  22  (64.7%).  Neurological  complications  were  immune-­mediated  in  11/34  cases  (32.3%),
infection-­related  in  9  (26.5%),  drug-­related  in  5  (14.7%),  relapse-­related  in  5  (14.7%),  cerebrovascular  in  3  (8.8%),  and
due  to  a  CNS  neoplasia  in  1  (2.9%).  The  median  time  from  HSCT  to  neurological  symptoms  appearance  was  4.7  (0-­43.7)
months  (approximately  141  days).  Fourteen  patients  (41.2%)  presented  CMV  reactivation  and  13  (38.2%)  were  receiving
treatment  for  GVHD  at  the  onset  of  neurological  symptoms.  Three  (75%)  of  the  4  drug-­related  neurological  toxicities  that
occurred  within  day  30  were  observed  in  patients  of  Asian  (2)  and  African  (1)  ethnicity.  Details  on  neurological
complications  according  to  etiology  and  time  of  onset  are  depicted  in  Figure  1.  
[01302]  Figure  1.  Classification  of  neurological  complications  according  to  etiology  and  time  of  onset.
Thirteen  of  34  patients  (38.2%)  died  due  to  the  neurological  complication  (relapse  of  disease  4,  immune-­mediated  3,
infection-­related  2,  drug-­related  2,  cerebrovascular  1,  CNS  malignancy  1)  with  a  median  time  from  symptoms  onset  to
death  of  2.3  (0.2-­22.4)  months.  Among  the  21  patients  who  survived,  2  (9.5%)  are  currently  presenting  long-­term  effects
(GVHD-­related  tetraplegia  and  sensitive  neuropathy,  respectively).
Conclusions:  Although  affecting  a  limited  number  of  patients,  in  our  series  neurological  complications  were  associated  to
a  significant  mortality  and  severe  long-­term  disabilities.  Multicentre  prospective  studies  using  a  common  classification
system  are  awaited  in  order  to  identify  the  real  incidence  and  risk  factors  of  neurological  complications  in  HSCT  patients.
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